Cargando…

Combination of gut microbiota and plasma amyloid-β as a potential index for identifying preclinical Alzheimer’s disease: a cross-sectional analysis from the SILCODE study

BACKGROUND: Plasma amyloid-β (Aβ) may facilitate identification of individuals with brain amyloidosis. Gut microbial dysbiosis in Alzheimer’s disease (AD) is increasingly being recognized. However, knowledge about alterations of gut microbiota in preclinical AD, as well as whether the combination of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheng, Can, Yang, Kun, He, Beiqi, Du, Wenying, Cai, Yanning, Han, Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8843023/ https://www.ncbi.nlm.nih.gov/pubmed/35164860 http://dx.doi.org/10.1186/s13195-022-00977-x

Ejemplares similares

Alterations of gut microbiota are associated with brain structural changes in the spectrum of Alzheimer's disease: the SILCODE study in Hainan cohort
por: He, Beiqi, et al.
Publicado: (2023)

Plasma β-Amyloid Levels Associated With Structural Integrity Based on Diffusion Tensor Imaging in Subjective Cognitive Decline: The SILCODE Study
por: Wang, Xiaoni, et al.
Publicado: (2021)

MCP-1 levels in astrocyte-derived exosomes are changed in preclinical stage of Alzheimer's disease
por: Wang, Ting, et al.
Publicado: (2023)

A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Heterogeneity in subjective cognitive decline in the Sino Longitudinal Study on Cognitive Decline(SILCODE): Empirically derived subtypes, structural and functional verification
por: Fu, Zhenrong, et al.
Publicado: (2023)

Chronic-Antibiotics Induced Gut Microbiota Dysbiosis Rescues Memory Impairment and Reduces β-Amyloid Aggregation in a Preclinical Alzheimer’s Disease Model
por: Bello-Medina, Paola C., et al.
Publicado: (2022)

Plasma neurofilament light chain and amyloid-β are associated with the kynurenine pathway metabolites in preclinical Alzheimer’s disease
por: Chatterjee, Pratishtha, et al.
Publicado: (2019)

The preclinical amyloid sensitive composite to determine subtle cognitive differences in preclinical Alzheimer’s disease
por: Hahn, Alice, et al.
Publicado: (2020)

The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review
por: Brand, Abby L., et al.
Publicado: (2022)

Gut microbiome alterations in preclinical Alzheimer’s disease
por: Jung, Joon Hyung, et al.
Publicado: (2022)

Altered gut microbiota and its metabolites correlate with plasma cytokines in schizophrenia inpatients with aggression
por: Deng, Hongxin, et al.
Publicado: (2022)

Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease
por: Wang, Jun, et al.
Publicado: (2011)

Cognitive Decline in Preclinical Alzheimer’s Disease: Amyloid-Beta versus Tauopathy
por: Huber, Colin M., et al.
Publicado: (2017)

Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer’s disease
por: Pascoal, Tharick A., et al.
Publicado: (2018)

Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk
por: Ott, Brian R., et al.
Publicado: (2016)

Asymmetric amyloid deposition in preclinical Alzheimer’s disease: A PET study
por: Kjeldsen, Pernille L., et al.
Publicado: (2022)

Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

An integrated neuroimaging-omics approach for the gut-brain communication pathways in Alzheimer’s disease
por: Sheng, Can, et al.
Publicado: (2023)

Gut-derived β-amyloid: Likely a centerpiece of the gut–brain axis contributing to Alzheimer’s pathogenesis
por: Jin, Jinghua, et al.
Publicado: (2023)

Injection of amyloid-β to lateral ventricle induces gut microbiota dysbiosis in association with inhibition of cholinergic anti-inflammatory pathways in Alzheimer’s disease
por: Qian, Xiao-hang, et al.
Publicado: (2022)

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease()
por: Chételat, Gaël, et al.
Publicado: (2013)

Beta-amyloid and Cortical Thickness Reveal Racial Disparities in Preclinical Alzheimer's Disease
por: McDonough, Ian M.
Publicado: (2017)

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study
por: Hanseeuw, Bernard J., et al.
Publicado: (2019)

Inflammatory plasma biomarkers in subjects with preclinical Alzheimer’s disease
por: Prins, Samantha, et al.
Publicado: (2022)

Plasma phosphorylated tau 217 in preclinical Alzheimer’s disease
por: Jonaitis, Erin M, et al.
Publicado: (2023)

A Comparison of Methods of Gut Microbiota Transplantation for Preclinical Studies
por: Mingaila, Jonas, et al.
Publicado: (2023)

Antibiotics, gut microbiota, and Alzheimer’s disease
por: Angelucci, Francesco, et al.
Publicado: (2019)

Gut Microbiota: Implications in Alzheimer’s Disease
por: He, Yixi, et al.
Publicado: (2020)

Nutrition, Gut Microbiota, and Alzheimer's Disease
por: Romanenko, Mariana, et al.
Publicado: (2021)

Gut Microbiota and Immunotherapy for Alzheimer’s Disease
por: Dai, Chun-Ling, et al.
Publicado: (2022)

Publisher Correction: Plasma p-tau231 and p-tau217 as state markers of amyloid-β pathology in preclinical Alzheimer’s disease
por: Milà-Alomà, Marta, et al.
Publicado: (2022)

Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease
por: Insel, Philip S., et al.
Publicado: (2017)

Is pathological aging a successful resistance against amyloid-beta or preclinical Alzheimer’s disease?
por: Murray, Melissa E, et al.
Publicado: (2014)

Amyloid-β and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease
por: Pascoal, T A, et al.
Publicado: (2017)

Amyloid β deposition and glucose metabolism on the long-term progression of preclinical Alzheimer's disease
por: Hatashita, Shizuo, et al.
Publicado: (2019)

Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum
por: Milà‐Alomà, Marta, et al.
Publicado: (2020)

Astrocyte reactivity influences the association of amyloid-β and tau biomarkers in preclinical Alzheimer’s disease
por: Pascoal, Tharick, et al.
Publicado: (2023)

Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease
por: Bellaver, Bruna, et al.
Publicado: (2023)

Plasma β-amyloid in Alzheimer’s disease and vascular disease
por: Janelidze, Shorena, et al.
Publicado: (2016)

Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes
por: Verberk, Inge M. W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_kd02368f6tlmgt3gnqessiocmo